Novel technology, high sensitive tissue testing, to analyze intra-tumor pharmacokinetics of anti-HER2 antibody drugs in breast cancer.

Hayashi, Mitsuhiro; Matsukane, Ryosuke; Tamura, Kenji; Yoshida, Masayuki; Yonemori, Kan; Imai, Toshio; Kinoshita, Takayuki; Hamada, Akinobu

doi:10.1200/jco.2018.36.15_suppl.e24228

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This aids in the assessment of the prognostic situation for breast cancer patients. 150 Moreover, SERS technology enables cancer prognosis monitoring by detecting noninvasive biomarkers present in urine, saliva, and intestinal fluid. These noninvasive monitoring methods are convenient and feasible and contribute to more accurate prognostic assessments.…”

Section: Sers In Tumor Prognostic Monitoringmentioning

confidence: 99%

“…Similarly, in breast cancer, SERS technology enhances the sensitivity and specificity of prognostic monitoring by detecting and analyzing the SERS signatures of HER2 proteins. This aids in the assessment of the prognostic situation for breast cancer patients 150 . Moreover, SERS technology enables cancer prognosis monitoring by detecting noninvasive biomarkers present in urine, saliva, and intestinal fluid.…”

Section: Sers In Tumor Prognostic Monitoringmentioning

confidence: 99%

See 1 more Smart Citation

Advancing clinical cancer care: Unveiling the power of surface‐enhanced Raman spectroscopy

Li,

Yang,

Zhang

et al. 2024

J Raman Spectroscopy

View full text Add to dashboard Cite

Tumors are characterized by abnormal cell growth, which leads to uncontrolled cell proliferation, invasion of surrounding tissues, and potential metastasis to other parts of the body. Current treatments for tumors include surgery, chemotherapy, radiotherapy, targeted therapy, and biological therapy. However, many tumors are detected at advanced stages, limiting the effectiveness of these treatments. Therefore, there is a need to develop more sensitive and efficient techniques to improve patient survival rates. Surface‐enhanced Raman scattering (SERS) technology is a highly sensitive molecular detection and characterization technique. It can be combined with histomorphology, immunolabeling assays, and molecular hybridization to achieve quantitative diagnosis at morphological, molecular, and genetic levels. SERS offers advantages such as objectivity, reproducibility, and comparability. However, there are challenges to address, including complex substrate or probe preparation, cumbersome data analysis, and signal reproducibility and reliability. To fully utilize the potential of SERS in the biomedical field and for clinical translation, it is important to optimize the technology and develop more sensitive, accurate, and reliable substrate or probe preparation and analysis methods. This review aims to comprehensively explain the mechanism and unique advantages of SERS technology and discuss its current status, challenges, and prospects in tumor‐related research.

show abstract

Section: Sers In Tumor Prognostic Monitoringmentioning

confidence: 99%

Section: Sers In Tumor Prognostic Monitoringmentioning

confidence: 99%